Literature DB >> 6151441

Corticosteroid therapy in asthma.

N E Dunlap, J D Fulmer.   

Abstract

Corticosteroids are useful in the treatment of both allergic and idiosyncratic asthma. Although the mechanisms of corticosteroid action in asthma are poorly understood, several possible sites of action have been proposed. Corticosteroids alter the cellular and vascular inflammatory response to bronchial injury, affect catecholamine action on airways, and alter the production of eicosanoids, all of which aid in the resolution of bronchospasm in asthmatic patients. Corticosteroids should only be used for the treatment of asthma after therapeutic levels of methylxanthines and beta agonists have been achieved. Although the optimal doses of corticosteroids in asthma have not been defined, guidelines exist to aid in therapy. In the treatment of status asthmaticus, the intravenous route of administration is preferable. Short courses of corticosteroids may be useful in the treatment of chronic asthma. When long-term corticosteroid therapy is the only option for control of bronchospasm, alternate-day and/or aerosolized corticosteroids are preferable to daily corticosteroids and are associated with fewer side effects. Corticosteroids are useful in the pregnant asthmatic patient when bronchospasm cannot be controlled with bronchodilators. The major risk to the fetus in pregnant asthmatics is hypoxia from uncontrolled bronchospasm, and not from therapy. However, the lowest possible dose of systemic corticosteroids needed to control symptoms, with or without the use of aerosolized corticosteroids, is recommended. All asthmatics who have needed systemic or aerosolized corticosteroids within 6 months prior to surgery should receive preoperative and post-operative corticosteroid therapy. For patients not usually on systemic corticosteroids, conversion to oral prednisone, with a rapid taper is recommended. Side effects from short-term corticosteroid therapy are minimal, with hyperglycemia and psychosis being the major concerns. Long-term steroid therapy has significant side effects, however, and use should be minimized. Suppression of the HPA axis is one of the most potentially dangerous side effects of corticosteroids, and therefore any patient who has been treated with corticosteroids for longer than 4 weeks should be evaluated for possible adrenal suppression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151441

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  7 in total

Review 1.  Lower airway obstruction in the PICU.

Authors:  S A Kecskes
Journal:  Indian J Pediatr       Date:  1990 Mar-Apr       Impact factor: 1.967

Review 2.  Asthma and athletes: therapy to compete.

Authors:  John M Weiler; Christine Malloy
Journal:  Clin Rev Allergy Immunol       Date:  2005-10       Impact factor: 8.667

3.  National Athletic Trainers' Association position statement: management of asthma in athletes.

Authors:  Michael G Miller; John M Weiler; Robert Baker; James Collins; Gilbert D'Alonzo
Journal:  J Athl Train       Date:  2005 Jul-Sep       Impact factor: 2.860

4.  Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit.

Authors:  I Federico Fernandez Nievas; Kanwaljeet J S Anand
Journal:  J Pediatr Pharmacol Ther       Date:  2013-04

5.  Risk of osteoporosis in men with chronic bronchitis.

Authors:  J P Praet; A Peretz; S Rozenberg; J P Famaey; P Bourdoux
Journal:  Osteoporos Int       Date:  1992-09       Impact factor: 4.507

Review 6.  Contemporary treatment of children with critical and near-fatal asthma.

Authors:  Steven L Shein; Richard H Speicher; José Oliva Proença Filho; Benjamin Gaston; Alexandre T Rotta
Journal:  Rev Bras Ter Intensiva       Date:  2016-06

7.  Inhibition of the production of mediators of inflammation by corticosteroids is a glucocorticoid receptor-mediated process.

Authors:  G S Madretsma; A P Dijk; C J Tak; J H Wilson; F J Zijlstra
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.